Postmenopausal Osteoporosis: Clinical Trials

14 trials for Postmenopausal Osteoporosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 4 unknown, 1 active not recruiting, 1 not yet recruiting. 14 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 214Completed 8, Unknown 4, Active not recruiting 1, Not yet recruiting 1
Phase 11Unknown 1

Follow Postmenopausal Osteoporosis: new trials by email Literature Review of Postmenopausal Osteoporosis trials Research Report on Postmenopausal Osteoporosis

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass
Denosumab, Placebo - Postmenopausal Osteoporosis, Low Bone Mass
Phase 2Not yet recruitingTranscenta Therapeutics (Hangzhou) Co., Ltd.1102026-10-312026-09-11
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)
AGA2118, Placebo - Postmenopausal Osteoporosis
Phase 2Active not recruitingAngitia Biopharmaceuticals3792024-10-312026-02-10
Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis
JMT103, Denosumab, Placebo - Postmenopausal Osteoporosis
Phase 2UnknownShanghai JMT-Bio Inc.2002022-04-212022-07-18
G56W1 in Women With Postmenopausal Osteoporosis
rhPTH(1-34) 28.2μg, rhPTH(1-34) 56.5μg, teriparatide acetate(Teribone™) - Postmenopausal Osteoporosis
Phase 1 / Phase 2UnknownShenzhen Salubris Pharmaceuticals Co., Ltd.1482018-10-012018-10-25
The Deferasirox-calcium-vitamin D3 Therapy for Postmenopausal Osteoporosis (PMOP)
Deferasirox and calcium-vitamin D3, Calcium-vitamin D3 - Postmenopausal Osteoporosis
Phase 2UnknownSecond Affiliated Hospital of Soochow University102018-01-152018-05-17
Molecular Mechanism of POP Kidney Yin Deficiency Syndrome From the Interventional Effects of CLCF1
Liuwei Dihuang Pills - Postmenopausal Osteoporosis
Phase 2UnknownFujian Academy of Traditional Chinese Medicine252012-01-012013-04-18
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women
PTH analog, Placebo, Forsteo (Teriparatide) - Postmenopausal Osteoporosis
Phase 2CompletedUnigene Laboratories Inc.972011-02-012013-03-01
MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)
MK-5442, Placebo to MK-5442, Alendronate Sodium - Osteoporosis, Postmenopausal Osteoporosis
Phase 2CompletedMerck Sharp & Dohme LLC5262009-11-012016-01-22
Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
Placebo to Romosozumab, Alendronate, Teriparatide - Low Bone Mineral Density, Postmenopausal Osteoporosis
Phase 2CompletedAmgen4192009-06-032022-09-22
A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
Previous denosumab - Low Bone Mass, Low Bone Mineral Density
Phase 2CompletedAmgen152009-06-012013-11-15
Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women
150 mg, 75 mg, 100 mg - Postmenopausal Osteoporosis
Phase 2CompletedWarner Chilcott2052009-05-012015-06-29
A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
Alendronate, Denosumab, Placebo - Postmenopausal Osteoporosis
Phase 2CompletedAmgen2472006-05-012014-07-25
Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
synthetic hPTH 1-34 - Postmenopausal Osteoporosis, Osteoporosis
Phase 2CompletedMassachusetts General Hospital802004-05-012013-10-30
Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.
Bazedoxifene, Placebo - Postmenopausal Osteoporosis
Phase 2CompletedWyeth is now a wholly owned subsidiary of Pfizer3752003-08-012007-12-20

Narrower conditions

Osteoporosis, Postmenopausal (14)  ·  Osteoporosis (6)  ·  Bone Diseases, Metabolic (3)  ·  Bone Diseases (1)  ·  Bone Resorption (1)  ·  Crisponi syndrome (1)  ·  Sclerosteosis (1)

Broader conditions

Metabolic Diseases (14)  ·  Musculoskeletal Diseases (14)  ·  Nutritional and Metabolic Diseases (14)  ·  Bone Diseases (13)  ·  Bone Diseases, Metabolic (11)  ·  Osteoporosis (8)

Interventions

Denosumab (4)  ·  Alendronate (3)  ·  Teriparatide (2)  ·  Calcium Carbonate (1)  ·  Cholecalciferol (1)  ·  Deferasirox (1)  ·  JTT 305 (1)  ·  Zoledronic Acid (1)  ·  bazedoxifene (1)  ·  parathyroid hormone (1-31) (1)  ·  romosozumab (1)

Sponsors

Amgen (3)  ·  Angitia Biopharmaceuticals (1)  ·  Fujian Academy of Traditional Chinese Medicine (1)  ·  Massachusetts General Hospital (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Second Affiliated Hospital of Soochow University (1)  ·  Shanghai JMT-Bio Inc. (1)  ·  Shenzhen Salubris Pharmaceuticals Co., Ltd. (1)  ·  Transcenta Therapeutics (Hangzhou) Co., Ltd. (1)  ·  Unigene Laboratories Inc. (1)  ·  Warner Chilcott (1)  ·  Wyeth is now a wholly owned subsidiary of Pfizer (1)

Countries

China (4)  ·  United States (3)  ·  Argentina (1)  ·  Denmark (1)  ·  Estonia (1)  ·  Poland (1)  ·  Ukraine (1)

Top investigators

Bettina S Nedergaard, MD (1)  ·  Chantell Wilson, PhD (1)  ·  Christence S Teglbjaerg, MD (1)  ·  Ivo Valter, MD (1)  ·  Joel S. Finkelstein, MD (1)  ·  Peter Alexandersen, MD (1)  ·  Ricardo Dent-Acosta, MD (1)  ·  Robert M. Neer, MD (1)  ·  Weibo Xia (1)  ·  Weibo Xia, Prof. (1)  ·  You-Jia Xu, Ph.D,M.D. (1)

Results publications

PMID 20839291, PMID 21111078, PMID 23234813, PMID 23719683, PMID 24382002, PMID 26556736, PMID 33606045, PMID 34530172, PMID 40686685

NIH funding

2008 (1), 2009 (1), P50AR044855 (1)